In-depth understanding of the working mechanism of OPG as a natural inhibitor of RANKL has led to development of Denosumab22, a now widely prescribed anti-RANKL mAb for osteoporosis, which essentially performs the exact function of OPG. The gene discussed is TNFSF11; the disease is osteoporosis.